section name header

Evidence summaries

Tnf-Alpha Inhibitors for Ankylosing Spondylitis

Anti-TNF agents (adalimumab, etanercept, golimumab, infliximab) improve pain, function and other symptoms of ankylosing spondylitis and appear to increase partial remission rates compared to placebo in the short-term (less than 24 weeks). They appear to be associated with a small increase in withdrawals due to adverse events. Level of evidence: "A"

Summary

A Cochrane review [Abstract] 1 included 21 short-term (24 weeks or less) studies with a total of 3 308 subjects; 18 contributed data to the mixed treatment comparison analysis: adalimumab (4 studies), etanercept (8 studies), golimumab (2 studies), infliximab (3 studies), and one head-to-head study (etanercept versus infliximab). Most studies permitted concomitant therapy of stable doses of disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, or corticosteroids, but allowances varied across studies.

Compared with placebo, patients on an anti-TNF agent were more likely to achieve an ASAS40 response (40% improvement in pain, function, and inflammation as measured by morning stiffness, and patient overall well-being) and ASAS partial remission by 6 months (table T1). There was improvement in physical function on a 0 to 10 scale (BASFI; table T2) with TNF-alpha inhibitors compared with placebo. There was greater reduction in spinal inflammation as measured by magnetic resonance imaging though the absolute differences were small and the clinical relevance of the difference was unclear.

TNF-alpha inhibitors for ankylosing spondylitis

Outcome/InterventionParticipants (studies)Relative effect (95% CrI)Assumed risk - placeboCorresponding risk - intervention (95% CrI)NNT (95% CI)
ASAS40
Adalimumab vs. placebo659 (2 studies)RR 3.53(2.49 to 4.91)13 per 10046 per 100(32 to 64)4 (2 to 6)
Etanercept (25 mg twice weekly or 50 mg once weekly) vs. placebo584 (3 studies)RR 3.31(2.38 to 4.53)13 per 10043 per 100(31 to 59)4 (3 to 6)
Golimumab vs. placebo429 (2 studies)RR 2.90 (1.90 to 4.23)13 per 10038 per 100(25 to 55)5 (3 to 9)
Infliximab vs. placebo355 (2 studies)RR 4.07(2.80 to 5.74)13 per 10053 per 100(36 to 75)3 (2 to 5)
ASAS partial remission
Adalimumab vs. placebo659 (2 studies)RR 6.28(3.13 to 12.78)3 per 10019 per 100(9 to 38)7 (3 to 16)
Etanercept (25 mg twice weekly or 50 mg once weekly) vs. placebo785(3 studies)RR 4.24(2.31 to 8.09)3 per 10013 per 100(7 to 24)11 (5 to 26)
Golimumab vs. placebo216(1 study)RR 5.18 (1.90 to 14.79)3 per 10016 per 100(6 to 44)8 (3 to 38)
Infliximab vs. placebo348(2 studies)RR 15.41(5.09 to 47.98)3 per 10047 per 100(16 to 90)3 (2 to 8)
CrI = credible interval; CI = confidence interval; NNT = number needed to treat
Physical function (BASFI 0 to 10 scale, lower is better)
InterventionParticipants (studies)The mean BASFI in the control groupsThe mean BASFI in the intervention groups (95% CrI)NNT to achieve the MCID of 0.7 points (95% CI)
Adalimumab vs. placebo786 (4 studies)5 points1.6 lower(2.2 to 0.9 lower)4 (3 to 5)
Etanercept (25 mg twice weekly or 50 mg once weekly) vs. placebo553(6 studies)5 points1.1 lower(1.6 to 0.6 lower)4 (4 to 6)
Golimumab vs. placebo429(2 studies)5 points1.5 lower(2.3 to 0.7 lower)4 (3 to 5)
Infliximab vs. placebo348(2 studies)5 points2.1 lower(2.7 to 1.4 lower)2 (2 to 3)
MCID = minimally important difference
When all the anti-TNF agents were combined against placebo, there was an increased risk of withdrawals due to adverse events in the anti-TNF group though the absolute increase in harm was small (1%, 95% CI 0% to 2%). Results for individual agents are shown in table T3. Due to low event rates, results on serious adverse events were inconclusive (table T3).

Adverse events

Outcome/InterventionParticipants (studies)Relative effect (95% CI or CrI)Assumed risk - placeboCorresponding risk - intervention (95% CI or CrI)
Withdrawals due to adverse events
Adalimumab vs. placebo659(2 studies)RR 1.69(0.35 to 10.84)7 per 100012 per 1000(3 to 80)
Etanercept (25 mg twice weekly or 50 mg once weekly) vs. placebo1 061(8 studies)RR 3.65(1.27 to 11.79)7 per 100026 per 1000(9 to 83)
Golimumab vs. placebo429(2 studies)RR 1.97 (0.36 to 17.51)7 per 100014 per 1000(3 to 123)
Infliximab vs. placebo424(3 studies)RR 1.77(0.43 to 8.46)7 per 100012 per 1000(3 to 59)
All anti-TNF agents versus placebo2 623(16 studies)Peto OR 2.44 (1.26 to 4.72)7 per 100016 per 1000(8 to 33)
Serious adverse events
Adalimumab vs. placebo659(2 studies)RR 0.92(0.26 to 3.93)15 per 100014 per 1000(4 to 59)
Etanercept (25 mg twice weekly or 50 mg once weekly) vs. placebo1 061(8 studies)RR 1.69(0.76 to 3.72)15 per 100025 per 1000(11 to 56)
Golimumab vs. placebo216 (1 study)RR 0.69(0.15 to 3.32)15 per 100010 per 1000(2 to 50)
Infliximab vs. placebo422 (3 studies)RR 2.53(0.76 to 11.09)15 per 100038 per 1000(11 to 166)
All anti-TNF agents versus placebo2 408(15 studies)Peto OR 1.45 (0.85 to 2.48)15 per 100022 per 1000(13 to 36)
Results for individual anti-TNF agents are based on the mixed treatment comparison analyses, and the 'All anti-TNF agents versus placebo' results are based on standard meta-analyses.
Differences between individual anti-TNF-agents were examined using indirect comparison methodology, and one head-to-head study of etanercept versus infliximab. Wide confidence intervals meant that results were inconclusive for evidence of differences in the major outcomes between different anti-TNF agents.

Clinical comments

Note

No evidence of an increase in serious adverse events was found, though event rates were low and studies had a short duration. Regulatory agencies have published warnings about rare adverse events of serious infections, including tuberculosis, malignancies and lymphoma.

Date of latest search: